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Introduction: Reduced monocyte human leukocyte antigen (mHLA)-DR surface expression in the late phase of
sepsis is postulated as a general biomarker of sepsis-induced immunosuppression and an independent predictor of
nosocomial infections.
However, traditional monitoring of mHLA-DR by flow cytometry has disadvantages due to specific laboratory
requirements. An mRNA-based HLA-DR monitoring by polymerase chain reaction (PCR) would improve the clinical
usage and facilitate conduction of large multicenter studies. In this study, we evaluated an mRNA-based HLA-DR
monitoring by quantitative real-time PCR (qRT-PCR) as an alternative method to traditional flow cytometry.
Methods: Fifty-nine patients with sepsis and blood culture growing pathogenic bacteria were studied. Blood samples
were collected at day 1 or 2 after admission, for measurement of mHLA-DR by flow cytometry and mRNA expression of
HLA-DRA and class II transactivator (CIITA) by qRT-PCR. Blood samples from blood donors were used as controls (n = 30).
Results: A significant reduced expression of mHLA-DR, HLA-DRA, and CIITA was seen in septic patients compared with
controls. HLA-DRA mRNA level in whole blood was highly correlated with surface expression of mHLA-DR.
Conclusions: Patients with sepsis display a diminished expression of HLA-DR at the monocyte surface as well as in the
gene expression at the mRNA level. The mRNA expression level of HLA-DRA monitored by qRT-PCR correlates highly with
surface expression of HLA-DR and appears to be a possible future biomarker for evaluation of immunosuppression in
sepsis.Introduction
Septic syndromes caused by bloodstream infections repre-
sent a major health-care problem worldwide [1], and sepsis
is the leading cause of mortality in non-cardiac intensive
care units (ICUs) [2]. The mortality rate of severe sepsis re-
mains high (approximately 30%) despite improved clinical
management algorithms [3]. In a recent retrospective study
of the outcome in 999 patients with severe sepsis, the over-
all mortality was 31%, and the highest incidence of deaths
(67.3%) was in the late phase [4].
The initial phase of severe sepsis is often characterized
by an intense hyperinflammation with massive release of* Correspondence: sara.cajander@orebroll.se
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reproduction in any medium, provided the orproinflammatory cytokines. For many years, this “cyto-
kine storm” was thought to be responsible for the high
mortality rate and multiple organ dysfunction in septic
syndromes [5,6]. However, in spite of numerous drug
trials aiming to counteract the proinflammatory activa-
tion, the results have been disappointing [7-10]. In
2011, the worldwide PROWESS (Recombinant Human
Activated Protein C Worldwide Evaluation in Severe
Sepsis) SHOCK trial resulted in a withdrawal of recom-
binant protein C (Xigris; Eli Lilly and Company,
Indianapolis, IN, USA), because of its demonstrated
lack of clinical efficacy [11].
Many patients who survive the initial critical phase of
septic shock die at a later time point due to secondary in-
fections with pathogens normally deleterious only in im-
munocompromised hosts [4,12]. Thus, investigators of a
new paradigm have proposed that a hypoinflammatoryal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[5,6,13-17]. A recent post-mortem study showed that pa-
tients who die in the ICU following sepsis display bio-
chemical, flow cytometric, and immunohistochemical
findings consistent with immunosuppression [18].
Immunostimulation by granulocyte-macrophage colony-
stimulating factor (GM-CSF) and interferon-gamma (IFN-γ)
during the state of sepsis-induced immunosuppression
might be a promising therapeutic option to reverse this
anergy [19,20]. However, since immunostimulants can
be deleterious when given in the hyperinflammatory state
of sepsis, a safe and stable biomarker of the immunologic
state is crucial. Downregulation of monocyte human
leukocyte antigen-DR surface expression (mHLA-DR) mea-
sured by flow cytometry is postulated as a general bio-
marker of sepsis-induced immunosuppression and acts as
an independent predictor of nosocomial infections [21].
However, the use of mHLA-DR as a marker of immuno-
suppression is not yet sufficiently evaluated in large multi-
center studies of patients with sepsis, and this is most likely
due to pre-analytical requirements and limitations in speci-
men handling. Flow cytometric measurements of mHLA-
DR require handling of blood samples within 4 hours [22],
hindering inclusion from centers lacking flow cytometry.
A global transcriptional downregulation of a gene
panel required for mHLA-DR expression has been dem-
onstrated in whole blood from patients with sepsis
[23,24]. If HLA-DR expression as a marker of immuno-
suppression could be monitored by quantitative real-
time polymerase chain reaction (qRT-PCR) instead of
traditional flow cytometry, it would facilitate future mul-
ticenter studies.
The aim of this study was to evaluate whether moni-
toring of HLA-DR by qRT-PCR supports previous re-
ports describing significant reduced expression levels of
HLA-DRA and class II transactivator (CIITA) in patients
with sepsis [23,24] and, furthermore, to assess how it




Ethical approval for the study was obtained from the
Ethics Committee (Central Review Board, Uppsala,
Sweden). This was a single-center study at Örebro
University Hospital Sweden. The study group consisted
of patients (n = 59) who had sepsis and positive blood
culture growing pathogenic bacteria and who were en-
rolled during a 19-month period. Three patients were
excluded from the 62 patients who were initially
recruited for the study: two patients had bacterial find-
ings regarded as a contamination (coagulase-negative
staphylococci) and no evidence of clinical infection,
and one patient did not fulfill inclusion criteria, due todelay in blood culture sampling. Sepsis severity definitions
(sepsis, severe sepsis, and septic shock) were based on
classic criteria defined by the American College of Chest
Physicians/Society of Critical Care Medicine [25]. When
criteria for sepsis, but not severe sepsis or septic shock,
were met, we defined it as non-severe sepsis. Blood cul-
tures were collected on admission day 0 from all patients
who had suspected infectious disease and who were ad-
mitted to the Department of Infectious Diseases and
Department of Internal Medicine. When blood cultures
showed growth of pathogenic bacteria within 1 or 2
days from admission, patients were consecutively en-
rolled in the study. All patients were included after in-
formed consent to participate and consent to publish.
At day 1 or 2 after admission day, blood samples for
both flow cytometry and mRNA-based monitoring of
HLA-DRA were obtained. Blood samples from blood do-
nors (n = 30) at the university hospital in Örebro were
randomly collected and used as controls. Comorbidity of
the patients with sepsis was assessed by Charlson comor-
bidity score [17].
Sampling
Sterile vacuum tubes (PAXgene Blood RNA tube; Pre-
AnalytiX GmbH, Qiagen group, Hilden, Germany) were
used in the sampling of peripheral whole blood for PCR
analysis. The PAXgene tubes were stored after sampling
in −80°C until further analysis. EDTA anticoagulant
tubes were used in the sampling of peripheral whole
blood for flow cytometry analysis of HLA-DR. The sam-
ples for flow cytometry were immediately placed on ice
and handled within 4 hours.
RNA isolation
RNA was prepared by using the PAXgene Blood RNA-kit
(PreAnalytiX GmbH, Qiagen group) in accordance with
the instructions of the manufacturer. The concentration
and purity of RNA were measured on a NanoDrop ND-
1000 Spectrophotometer (Agilent Technologies Inc., Santa
Clara, CA, USA) while using buffer (10 mM Tris–HCl
buffer, pH 7.5) as a blank. The ratio of absorbance at 260
and 280 nm was used to assess the purity. A ratio of ap-
proximately 2.0 was accepted as pure. The RNA prepar-
ation was kept frozen (−80°C) prior to use.
cDNA preparation
A volume corresponding to 100 ng of RNA was used in
synthesis (20 μL) of cDNA by using a High-capacity
cDNA reverse transcription kit (#4368814; Applied
Biosystems, Foster City, CA, USA) in accordance with
supplied instructions. This synthesis was performed in
duplicate, and the products were pooled prior to use. A
non-sample preparation was also performed as an in-
ternal control. The cDNA was stored at −80°C.
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The expression levels of mRNA encoding a non-
polymorphic region of the alfa-chain of the HLA-DR mol-
ecule (HLA-DRA) and the mRNA coding for CIITA, the
major regulator of the transcription of HLA-DR genes,
were obtained by quantitative real-time PCR.
The cDNA (2 μL) was tested in the following
TaqMan Gene expression assays (FAM-labeled MGB
probes) (Applied Biosystems/Life Technologies Europe BV,
Stockholm, Sweden): HLADRA-A (Lot Hs00219575_ml),
RefSeq: NM-019111.4, Amplicon 97 base pairs (bp); CIITA
(Lot Hs00172094_ml), RefSeq: NM_000246.3, Amplicon 57
bp; and peptidylpropylisomeras B (PPIB) (Lot Hs00168719_
ml), RefSeq: NM_000942.4, Amplicon 67 bp.
These assays were run in triplicates (20-μL reactions)
in a 96-well (MicroAmp fast, part #4346907) fast format
(Applied Biosystems) and a relative quantification
mode, using the TaqMan Universal MasterMix (Applied
Biosystems, part #4352042, No AmpErase UNG) on a
ABI7900HF Fast Real-Time PCR-instrument (Applied
Biosystems) using the recommended two-step fast-program
for 40 cycles. Nuclease-free water samples (Life Technolo-
gies Europe BV) were used as a negative control and cali-
brator. The resulting PCR data were controlled for errors,
which were removed prior to detector-centric analysis.
Samples with errors in amplification triplicates were re-run
in a new plate, and analyzed in the same way. The intra-
assay variation within triplicates was low: change in thresh-
old cycle (ΔCt) standard deviation (SD) was less than 0.1.
Data from every separate plate (n = 12) were analyzed by
using automatic threshold and baseline and a detector-
centric mode (SDS2.3 and RQ manager 1.2; Applied
Biosystems).
The resulting average ΔCt values for the samples versus
the reference gene PPIB were used in calculating the fold
change assuming equal efficiency for all three assays within
the same sample and run. PPIB was used as reference gene
because of its previously described stability in inflamma-
tory conditions [26]. The Ct value for PPIB was an average
of 25.5 (SD of 0.77) for the 12 separate PCR plates.
Before the clinical samples were run, efficiency calcu-
lations of the individual assays were performed on sam-
ple dilutions to verify similar activity of the PCR in the
used gene expression assays. The compared gene assays
were comparable in efficiency and over 96% for cDNA
from samples and controls. The inter-assay variation of
the ratios between different runs and samples (n = 14)
were an average of ±14% for both genes. The differences
in Ct value for a separate sample were less than 0.5 be-
tween the different runs in 13 out of 14 samples.
Flow cytometry
The expression of cell surface HLA-DR on monocytes
was assessed at day 1 or 2 after admission by standardizedflow cytometry [22]. Antibody staining was performed
within 4 hours after sampling by using QuantiBRITE™
Anti–HLA-DR PE*/Anti-Monocyte PerCP-Cy5.5 (BD
Biosciences, San Jose, CA, USA) and QuantiBRITE™
PE* (BD Biosciences) in accordance with the instruc-
tion of the manufacturer. A FC500 (Beckman Coulter,
Fullerton, CA, USA) equipped with an argon laser (488
nm) and HeNe laser (633 nm) and EXPO 32 software
(Kaluza v1.2, Beckman Coulter) was used for data ana-
lysis, and results are expressed as number of antibodies
bound per cell (AB/c).
Statistical analysis
Groups were compared by the Mann–Whitney U test
(significance level P <0.05). Spearman rank correlation
coefficient was used for calculation of significant correl-
ation between the two different methods. Significant cor-
relation was set at the 0.01 level (two-tailed). Data are
given as median ± interquartile range (IQR).
Results
Characteristics of patients with sepsis
The study group consisted of 59 patients with sepsis and
concomitant bacteremia. Forty-eight patients were defined
as non-severe sepsis, 8 patients as severe sepsis, and 3 pa-
tients with septic shock. Twelve patients (20%) were admit-
ted to the ICU (Gram-positive n = 7, Gram-negative n = 5).
Among the 48 patients with non-severe sepsis, 25 patients
had Gram-negative etiology, 21 Gram-positive, and 2 were
miscellaneous (polymicrobial). Median age in the group
of patients with sepsis was 69 years. Sex distribution
was female n = 28 (47.5%) male n = 31 (52.2%). Median
Charlson comorbidity score was 1.0 (Table 1).
Characteristics of blood donors
The median age in the control group was 63 years. Sex
distribution was female n = 8 (26.7%) and male n = 22
(73.3%).
Monocyte surface expression of HLA-DR
In patients with sepsis (n = 59), the median value of
mHLA-DR was 19,007 AB/c, and IQR was 11,488 to
36,654 AB/c. In blood donors (n = 30), the median value
of mHLA-DR was 38,251 AB/c (IQR 31,997 to 41,113).
Statistical analysis demonstrated a significant difference
in surface expression between septic patients and con-
trols (P <0.0001) (Figure 1).
HLA-DRA and CIITA mRNA levels in whole blood
In patients with sepsis (n = 59), the median level of
HLA-DRA ratio was 2.83 (IQR 0.97 to 4.73). In healthy
donors (n = 30), the median of HLA-DRA ratio was 3.75
(IQR 3.46 to 4.77). A statistically significant difference in
mRNA expression of HLA-DRA levels was seen between
Table 1 Characteristics of patients with sepsis, Gram-staining, and HLA-DR expression
Sepsis severity Gram-staining Charlson comorbidity score Sex
Non-severe Severe Shock G+ G- 0 1-2 3-4 >5 Male Female
N (%) 48 (81.4) 8 (13.6) 3 (5.1) 29 (49.2) 27 (45.8) 20 (33.9) 28 (47.4) 8 (13.6) 3 (5.1) 31 (52.5) 28 (47.5)
mHLA-DR AB/cell
Median value 23,891 12,659 10,564* 12,482 30,938 18,606 21,475 29,178 7,398* 18,267 19,764
IQR 12,773-45,370 8,949-21,087 9,262-22,480 18,267-51,908 10,653-57,296 12,985-35,502 11,085-39,176 9,710-40,961 12,571-33,099
HLA-DRA ratio
Median value 3.37 1.47 0.62* 2.12 4.02 2.83 3.16 3.33 0.37* 2.94 2.83
IQR 1.78-5.48 0.95-3.7 0.88-3.64 1.96-6.72 0.98-6.71 1.78-4.81 1.23-4.41 0.93-4.43 1.04-5.29













Figure 2 HLA-DRA in relation to mHLA-DR. mRNA expression
levels of HLA-DRA in whole blood and monocyte surface expression






Figure 1 HLA-DR expression in septic patients with different sepsis severity. mRNA expression levels (A) and monocyte surface expression
(B) of human leukocyte antigen (HLA)-DR at day 1 or 2 after admission. Statistical differences between septic patients and controls were demonstrated
in both HLA-DRA (A) (P = 0.036) and mHLA-DR (B) (P <0.0001) expression. Significant differences were demonstrated in HLA-DRA (A) (P = 0.009) and
mHLA-DR (B) (P = 0.029) expression when the severity groups of non-severe (n = 48) and severe sepsis/septic shock (n = 11) were compared.
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The median level of CIITA ratio in patients with sepsis
was 0.14 (IQR 0.06 to 0.21) and was significantly lower
than in the control group (P <0.0001). Median CIITA
level in healthy controls was 0.36 (IQR 0.25 to 0.43).
Correlations between mRNA expression levels (HLA-DRA,
CIITA) and surface expression of HLA-DR
In patients with sepsis (n = 59), blood samples were
collected simultaneously for HLA-DR monitoring by qRT-
PCR (transcripts of HLA-DRA and CIITA) and flow cytom-
etry. A statistically significant strong correlation (r = 0.842,
P <0.0001) was seen between surface mHLA-DR and
mRNA levels of HLA-DRA. The relationship between
HLA-DRA and mHLA-DR is shown in Figure 2.
Expression of HLA-DRA and mHLA-DR in sepsis caused by
Gram-negative and Gram-positive bacteria
In non-severe sepsis caused by Gram-positive bacteria
(n = 21), HLA-DRA and mHLA-DR expression was signifi-
cantly lower compared with healthy controls (P = 0.006 and
P <0.0001, respectively). There was no significant difference
in HLA-DRA or mHLA-DR expression in non-severe sep-
sis (n = 24) caused by Gram-negative bacteria compared
with controls (P = 0.310, P = 0.648). Significant differences
in HLA-DR expression measured by either qRT-PCR or
flow cytometry were observed between the non-severe
groups of Gram-positive and Gram-negative etiology
(HLA-DRA P = 0.022; mHLA-DR P = 0.003) (Figure 3).
Expression of HLA-DRA and mHLA-DR in relation to sepsis
severity
There were significant differences in both mHLA-DR
and HLA-DRA expression between the two groups of
non-severe (n = 48) and severe (n = 11) sepsis/septic
shock (mHLA-DR P = 0.029, HLA-DRA P = 0.009).Discussion
To reduce mortality in sepsis, it is important to focus on
the late phase of sepsis, representing the period with a
significantly higher death rate. Given this, it is likely to
believe that the immunosuppressive state, described as a
common feature of the late phase of sepsis, plays a piv-
otal role in the persisting high mortality rate.
In terms of clinical information, it has been suggested
to perform mHLA-DR analysis routinely on ICU pa-
tients in order to evaluate the immune function [27]. So
far, flow cytometry is considered the gold standard in
HLA-DR monitoring. However, flow cytometry has im-
portant practical limitations: (a) results vary dramatically
A BP=0.022
P=0.003
Figure 3 HLA-DR expressions in Gram-positive and Gram-negative non-severe sepsis. mRNA expression levels (A) and monocyte surface
expression (B) of human leukocyte antigen (HLA)-DR at day 1 or 2 after admission. Significant differences were demonstrated in both mRNA
expression levels of HLA-DRA (A) (P = 0.022) and monocyte surface expression of HLA-DR (B) (P = 0.003) when the groups of Gram-positive and
etiology were compared.
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samples have to be analyzed immediately and cannot be
stored for later analyses, and (c) samples cannot be col-
lected from health-care units without laboratory equip-
ment for flow cytometry. These important limitations of
traditional HLA-DR monitoring clearly hamper the clin-
ical usage and feasability of larger multicenter studies re-
quired in this field. An mRNA-based approach for HLA-
DR expression allows samples to be stored in a frozen
state, to be collected at different sites, and to be sent to
a collaborating laboratory for later analysis.
In this study, we investigated HLA-DR expression in
59 patients with sepsis, all with blood cultures growing
pathogenic bacteria. Patients were included independ-
ently of sepsis severity or underlying disease, in contrast
to previous studies focusing on HLA-DR in severe sepsis
or septic shock [25]. A significantly lower HLA-DR ex-
pression in the total number of septic patients compared
with controls was observed in both mRNA expression
levels of HLA-DRA and CIITA from whole blood and in
monocyte surface expression of HLA-DR. A low expression
level of mRNA encoding CIITA, the major transactivator of
HLA-DR gene expression, represents indirectly a transcrip-
tional downregulation of HLA-DR genes in patients with
sepsis [23]. These results confirm the recently presented
pathophysiologic mechanism in sepsis HLA-DR expression,
suggesting a transcriptional downregulation of a gene panel
required for mHLA-DR expression [23,24].
To perform a valid method for quantitation of HLA-
DR expression at the mRNA level, it is important to
avoid inter-individual variations due to the genetic poly-
morphism in the HLA-DR genes. Hence, we found it
preferable to monitor HLA-DRA, encoding the non-
polymorphic region of the alfa-chain of the HLA-DR
molecule.
A high correlation between the mRNA expression
level of HLA-DRA by qRT-PCR in whole blood and the
surface expression of HLA-DR by flow cytometry wasdemonstrated in this study. The loss of HLA-DR has
previously been explained by downregulation of a gene
panel essential for mHLA-DR expression, but so far the
correlation with mHLA-DR has been studied in only
minor patient cohorts [23,24,28]. The different tech-
niques of HLA-DR monitoring in this study correlate
highly but are not analogous since we measure the
HLA-DR expression at two different levels and in differ-
ent blood cells. Monitoring of HLA-DRA measures the
mRNA expression level in whole blood encoding genetic
information important for the molecule structure in all
blood cells expressing HLA-DR. In contrast, mHLA-DR
monitors the surface expression only on monocytes.
In our study, PPIB was used as the reference gene be-
cause of its stability in inflammatory conditions [26].
The choice of reference gene and difference in patient
cohort size might explain why our results show a higher
correlation coefficient compared with the work by Le
Tulzo and colleagues (r = 0.764) in which Abelson (ABL)
was used as the reference gene [23].
In contrast to Pachot and colleagues [24], we noted an
overlap in HLA-DR expression between the septic and
healthy patients. This might be explained by our wide
inclusion criteria, which also included septic patients
with non-severe sepsis. The majority (80%) of patients in
the present study were not admitted to the ICU.
The expression levels of HLA-DR in the present study
were lower in the groups of severe sepsis and septic shock
compared with non-severe sepsis. Because of the small
number of patients in the severity groups, statistical signifi-
cance was reached only when the combined groups of
severe sepsis and septic shock were compared with non-
severe sepsis. However, variations in HLA-DR expression
according to sepsis severity show the similar profile when
monitored by either qRT-PCR or flow cytometry.
Differences in HLA-DR expression are seen in Gram-
positive and Gram-negative sepsis. While HLA-DR is
significantly lower in sepsis caused by Gram-positive
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difference in HLA-DR expression when comparing
Gram-negative sepsis and controls, although the patients
were scored into the same severity group. This variation
is seen when monitoring HLA-DR by cell surface ex-
pression as well as at the mRNA expression level.
The reason for possible differences in HLA-DR expres-
sion between Gram-positive and Gram-negative sepsis is
unknown, and data pointing toward differences are pre-
liminary and should be interpreted carefully due to statis-
tical shortcomings of post-hoc analyses.
The high correlation between mRNA levels of HLA-DRA
and surface expression of HLA-DR and similarity in
displaying variations according to sepsis severity and Gram-
staining results indicates a possible consistency between the
two methods. However, some limitations of the present
study should be considered before solid conclusions can be
drawn. The inclusion criteria consisting of early diagnosed
bloodstream-positive sepsis lead to recruitment of patients
with a variation in sepsis severity. The majority of patients
in the present study group were scored in the non-severe
septic group with only slightly depressed HLA-DR expres-
sion. Simplified Acute Physiology Score II (SAPS II) and
Sequential Organ Failure Assessment (SOFA) score were
not registered, because of the low percentage of patients ad-
mitted to the ICU. Future studies evaluating the agreement
between methods in the late sepsis phase and its relation to
the burden of secondary infections will be required to state
whether this PCR-guided monitoring of immunosuppres-
sion may be preferable as a diagnostic tool.
While flow cytometry requires expensive equipment and
work load, there is a rapid development of PCR tests with
very little hands-on time [27,29]. If commercial easy-
handled qRT-PCR assays for mRNA HLA-DR became
available, cellular immune function could more easily be
monitored to support management of patients with sepsis.
Conclusions
Patients with sepsis display a diminished expression of
HLA-DR at the monocyte surface as well as in the gene
expression at the mRNA level. The mRNA expression
level of HLA-DRA monitored by qRT-PCR correlates
highly with surface expression of HLA-DR and appears
to be a promising future biomarker for evaluation of im-
munosuppression in sepsis.
Key messages
 Patients with sepsis display a diminished expression
of HLA-DR at the monocyte surface as well as in
the gene expression at the mRNA level.
 The mRNA levels of HLA-DRA and the monocyte
surface expression of HLA-DR correlate highly in
the early sepsis phase.Abbreviations
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